StriVectin® Announces Recognition of New Retinol Technology by the World Congress of Cosmetic Dermatology

StriVectin-AR™ Advanced Retinol Eye Treatment and Day Treatment with SPF 30 Performs Better Than Prescription Strength Retinol*

Jun 27, 2013, 10:00 ET from StriVectin(R)

NEW YORK, June 27, 2013 /PRNewswire/ -- StriVectin®, a leader in the global skincare market, announces today the acceptance of their breakthrough and clinically proven Advanced Retinol technology by the Organizing Committee of the 9th World Congress of Cosmetic Dermatology which is made up members of the International Academy of Cosmetic Dermatology (IACD).

(Photo: )

StriVectin is eager to showcase to the dermatological community their clinical findings around this revolutionary technology. Their 4 week results show that their breakthrough Advanced Retinol technology, combined with their multi-patented NIA-114® molecule, is clinically proven to perform better than prescription strength Retinol, in various measurements without irritation and skin sensitivity. This technology can be found in the new StriVectin-AR™ Advanced Retinol Eye Treatment and Day Treatment with SPF 30.

They submitted an abstract to the committee titled "To Determine the Ability of NIA-114® Molecule plus Retinol to Effect Changes in Facial Skin Elasticity, Moisturization and the Appearance of Facial Lines and/or Wrinkles Compared to Prescription Retinoid, for their Review." The abstract includes; Background and Aims, Methods, Results, Conclusions as well as multiple references.

It showcased the company's result which were determined after 4 weeks of usage during a 12-week, randomized, baseline controlled, double-blind, clinical trial conducted by a third party independent testing facility. The study looked at four subject groups of 130 females between the ages of 40 and 65. The primary objective of this trial was to determine the ability of an eye cream and an SPF day cream containing NIA-114® and non-prescription retinol to affect changes in skin elasticity and moisturization and to determine the potential of the test materials to reduce the appearance of facial lines and wrinkles when compared to Tretinoin and a placebo without the accompanying irritation or potential side effects.

StriVectin discovered that when their multi-patented NIA-114® molecule was combined with Retinol, NAD (the bioactive form of Niacin or Vitamin B3) is required to convert Retinol (Vitamin A) to its bioactive, more efficacious form of Retinoic Acid in the skin.  The proprietary NIA-114® molecule is one of the most active forms of Niacin and compared to Niacinamide, it is able to increase the NAD content in the skin to help fuel Retinol conversion.  Furthermore, only NIA-114® has the unique ability to absorb deeply into the skin to strengthen and build-up the skin barrier, enhancing its durability and in turn improving its tolerability of Retinol and reducing sensitivity. 

"We've spent the last 30 years researching the skin care benefits of NIA-114®, and when combined with powerful new actives targeting specific concerns, we saw extraordinary skin repair results.  In addition, our studies showed a significant improvement in skin barrier function important for overall skin health benefits," said Drs. Myron and Elaine Jacobson, biochemists and university professors who have served as StriVectin's Chief Scientists.  

The 9th World Congress of Cosmetic Dermatology will be held in Athens, Greece, from June 27-30th, 2013.

*At 4 weeks via instrumentation and consumer evaluation

About StriVectin:
StriVectin® is the largest independent prestige skin care company, focusing on clinical anti-aging skin care solutions. Backed by science and rigorous clinical validation, StriVectin is at the forefront of skin care technology and product innovation.  Its unique dual-use repair cream StriVectin-SD Intensive Concentrate is a best-seller around the world, and is often credited with starting the clinical cosmeceutical skin care category. StriVectin products are sold through department stores and specialty retailers in North America, Europe, the Middle East and Asia. The company maintains corporate offices in New York, NY.  For more information, visit

About the International Academy of Cosmetic Dermatology (IACD):
The purpose of our academy is new and unrivaled, bringing together dermatologists and cosmetic surgeons with members of the pharmaceutical and cosmetic industry. Cosmetic and pharmaceutical chemists will have the opportunity for an open and free interchange with physicians in an atmosphere conducive to learning.

About the 9th World Congress of Cosmetic Dermatology:
The World Congresses are usually hosted by National Organizations in their own country and in Representation of IACD. In the year 2013, this honour fell upon the Dermatological Clinic of the Medical School of the University of Athens and the Hellenic Society of Dermatology and Venereology. This distinction bestowed to Greece also displays an appreciation for Greek Dermatologists and Scientists in the field who have been entrusted to host such a meeting and who guarantee to provide the highest world standards in doing so.

Press Contact:

Lisa Lauri, (212) 220-3478

SOURCE StriVectin(R)